AMRI Partners up in Drug Discovery Amid a Corporate Turnaround
Wednesday, June 3, 2015
Source: Fierce CRO
Contract drugmaker AMRI ($AMRI) is shifting some of its focus to early-stage R&D, partnering up with a neighboring biotech to expand its capabilities in drug discovery.
AMRI, which does most of its business in manufacturing, has signed on to market HarkerBIO's discovery services to its biopharma clients around the world. In a three-year deal, AMRI gets access to its partner's technology for identifying and designing new drug candidates, while HarkerBIO taps the larger company's reach and capacity. Neither company is disclosing financial details.